Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Pemetrexed is a chemotherapeutic, antimetabolite agent that has been used in oncology to treat diseases such as metastatic non-small cell lung cancer and unresectable malignant pleural mesothelioma. Pemetrexed use may result in pseudocellulitis, which presents as poorly demarcated patches or plaques with erythema, edema, warmth, and tenderness. These lesions can present unilaterally or bilaterally on the lower extremities. The histologic appearance includes vacuolar interface dermatitis, squamous metaplasia of eccrine coils and ducts, sparse mixed neutrophilic and lymphocytic interstitial inflammatory infiltrate, and widened subcutaneous fibrous septa with cystic fat degeneration. We present the case of a 58-year-old woman with non-small cell lung cancer and pemetrexed-induced pseudocellulitis with distinctive histological features. The clinical appearance of patients with this hypersensitivity condition may mimic cellulitis, emphasizing the importance of increased awareness and consideration of pseudocellulitis in the differential diagnosis of patients on chemotherapy to avoid unnecessary hospitalization and treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cup.14785 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer.
JAMA Netw Open
September 2025
Oncostat U1018, Institut National de la Santé et de la Recherche Médicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France.
Importance: Antibiotics, steroids, and proton pump inhibitors (PPIs) are suspected to decrease the efficacy of immunotherapy.
Objective: To explore the association of comedications with overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC).
Design, Setting, And Participants: This nationwide retrospective cohort study used target trial emulations of patients newly diagnosed with NSCLC from January 2015 to December 2022, identified from the French national health care database.
Aucubin inhibits the activity of lung cancer stem-like cells by targeting degradation of β-catenin.
J Pharm Pharmacol
September 2025
Department of Clinical Pharmacy, Hebei Medical University Third Hospital. No. 139 Ziqiang Road, Qiaoxi District, Shijiazhuang 050051, China.
Objectives: To investigate the antitumor effects of aucubin (AC) in non-small cell lung cancer (NSCLC) and uncover its plausible mechanism against lung cancer stem-like cells (LCSCs).
Methods: In vitro experiments included MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a reagent commonly used for cell viability assay) and colony formation assays to assess anti-proliferative effects on A549 and NCI-H1975 lung cancer cell lines, wound healing and Transwell invasion assays to evaluate inhibition of cell migration and invasion, tumorsphere-formation experiments to detect changes in NSCLC cell stemness, as well as Western blot and quantitative reverse transcription polymerase chain reaction (qRT-PCR) analyses to measure the expression of LCSC markers (CD44, CD133, Oct4, and Nanog). In vivo experiments were conducted to observe the impact of AC on NSCLC metastasis and mouse survival rates.
Development and validation of a novel nomogram model for predicting postoperative survival of T4N0M0 NSCLC: a population-based survival analysis.
Int J Surg
September 2025
Department of Thoracic Surgery, Changchun Tumor Hospital.
Objective: The risk factors of postoperative survival in T4N0M0 NSCLC patients are not fully understood. This study aimed to develop and validate a nomogram model for predicting postoperative survival in patients with T4N0M0 non-small cell lung cancer (NSCLC).
Methods: Clinicopathological data of patients were collected from Surveillance, Epidemiology, and End Results (SEER) database.
Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy.
Front Immunol
September 2025
Department of Thoracic Surgery, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, Guangdong, China.
Background: Lung cancer remains the leading cause of cancer-related mortality globally, primarily due to late-stage diagnosis, molecular heterogeneity, and therapy resistance. Key biomarkers such as EGFR, ALK, KRAS, and PD-1 have revolutionized precision oncology; however, comprehensive structural and clinical validation of these targets is crucial to enhance therapeutic efficacy.
Methods: Protein sequences for EGFR, ALK, KRAS, and PD-1 were retrieved from UniProt and modeled using SWISS-MODEL to generate high-confidence 3D structures.
Exceptional Response to Immunotherapy-based Treatment in Compound -Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report.
J Immunother Precis Oncol
August 2025
Department of Medical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) with limited treatment options and poor prognosis. mutations generally respond to tyrosine kinase inhibitors (TKIs)-based targeted therapy but are typically associated with resistance to immunotherapy. We report a case of oligometastatic PSC harboring compound mutations (p.
View Article and Find Full Text PDF